- Home
- SYBX vs IMRN Comparison
SYBX vs IMRN Comparison
Compare SYBX & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- IMRN
- Stock Information
- Founded
- SYBX N/A
- IMRN 1994
- Country
- SYBX United States
- IMRN Australia
- Employees
- SYBX N/A
- IMRN N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SYBX Health Care
- IMRN Health Care
- Exchange
- SYBX Nasdaq
- IMRN Nasdaq
- Market Cap
- SYBX 17.0M
- IMRN 15.0M
- IPO Year
- SYBX N/A
- IMRN N/A
- Fundamental
- Price
- SYBX $1.42
- IMRN $1.96
- Analyst Decision
- SYBX Hold
- IMRN Strong Buy
- Analyst Count
- SYBX 3
- IMRN 1
- Target Price
- SYBX $1.00
- IMRN $5.00
- AVG Volume (30 Days)
- SYBX 74.6K
- IMRN 6.0K
- Earning Date
- SYBX 11-12-2024
- IMRN 12-31-2024
- Dividend Yield
- SYBX N/A
- IMRN N/A
- EPS Growth
- SYBX N/A
- IMRN N/A
- EPS
- SYBX N/A
- IMRN N/A
- Revenue
- SYBX $2,777,000.00
- IMRN $3,271,194.00
- Revenue This Year
- SYBX N/A
- IMRN N/A
- Revenue Next Year
- SYBX N/A
- IMRN N/A
- P/E Ratio
- SYBX N/A
- IMRN N/A
- Revenue Growth
- SYBX 292.23
- IMRN 171.67
- 52 Week Low
- SYBX $1.22
- IMRN $1.59
- 52 Week High
- SYBX $5.12
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- SYBX 48.54
- IMRN 45.89
- Support Level
- SYBX $1.36
- IMRN $2.05
- Resistance Level
- SYBX $1.88
- IMRN $2.23
- Average True Range (ATR)
- SYBX 0.09
- IMRN 0.17
- MACD
- SYBX -0.01
- IMRN -0.00
- Stochastic Oscillator
- SYBX 11.54
- IMRN 29.69
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.